scPharmaceuticals Inc. - Common Stock, par value $0.0001 per share (SCPH) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2017 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
SCPH
Shares outstanding
53,364,241
Price per share
$5.67
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
0
Total reported value
$0
Share change
-39,023,744
Value change
-$221,264,031
Number of holders
0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of scPharmaceuticals Inc. - Common Stock, par value $0.0001 per share (SCPH) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GLAZER CAPITAL, LLC 4.6% $11,829,640 2,474,820 Glazer Capital, LLC 02 Sep 2025
KING LUTHER CAPITAL MANAGEMENT CORP 4% -43% $11,982,841 -$8,674,586 2,128,391 -42% Luther King Capital Management Corporation 30 Sep 2025

As of 31 Dec 2025, 0 institutional investors reported holding 0 shares of scPharmaceuticals Inc. - Common Stock, par value $0.0001 per share (SCPH). This represents 0% of the company’s total 53,364,241 outstanding shares.

Institutional Holders of scPharmaceuticals Inc. - Common Stock, par value $0.0001 per share (SCPH) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$221,264,031 $5.67 0
2025 Q3 40,958,051 $232,212,551 +$31,413,737 $5.67 108
2025 Q2 38,194,973 $145,545,847 +$3,415,856 $3.81 95
2025 Q1 37,545,308 $98,742,458 -$7,793,831 $2.63 87
2024 Q4 39,775,602 $140,807,820 +$5,279,129 $3.54 84
2024 Q3 37,253,566 $169,822,547 +$42,711,046 $4.56 93
2024 Q2 27,815,340 $121,012,490 +$4,504,277 $4.35 77
2024 Q1 26,737,974 $134,225,727 -$7,908,753 $5.02 76
2023 Q4 27,975,859 $175,412,395 -$21,478,357 $6.27 79
2023 Q3 29,932,073 $213,117,843 +$9,111,651 $7.12 73
2023 Q2 28,536,920 $290,787,599 +$40,687,005 $10.19 81
2023 Q1 24,606,169 $223,185,472 +$38,842,993 $9.07 63
2022 Q4 21,410,510 $153,514,412 +$53,537,608 $7.17 59
2022 Q3 14,022,022 $91,281,927 -$10,765,163 $6.52 38
2022 Q2 15,695,145 $75,930,511 -$3,255,361 $4.82 37
2022 Q1 15,882,655 $90,121,602 -$464,823 $5.68 34
2021 Q4 15,935,241 $79,992,923 -$1,598,866 $5.02 29
2021 Q3 16,228,718 $107,917,705 +$1,557,655 $6.65 29
2021 Q2 16,027,286 $97,921,582 -$7,160,512 $6.11 35
2021 Q1 17,151,321 $114,054,500 +$1,499,774 $6.65 45
2020 Q4 16,944,254 $89,636,480 -$6,272,494 $5.29 46
2020 Q3 17,093,245 $127,345,487 -$3,281,426 $7.45 48
2020 Q2 17,536,133 $129,064,483 +$37,153,425 $7.36 51
2020 Q1 12,488,415 $92,413,167 +$10,168,930 $7.40 32
2019 Q4 11,121,954 $62,947,464 +$1,581,064 $5.65 27
2019 Q3 7,577,638 $44,502,550 +$1,469,868 $5.89 24
2019 Q2 7,370,534 $23,510,457 -$286,179 $3.19 28
2019 Q1 7,483,932 $22,451,653 -$1,275,253 $3.00 32
2018 Q4 7,846,766 $29,504,290 -$830,389 $3.76 32
2018 Q3 8,056,307 $47,291,256 -$192,971 $5.87 31
2018 Q2 8,090,838 $45,789,211 -$6,149,684 $5.66 37
2018 Q1 8,320,407 $103,170,760 +$6,465,196 $12.40 37
2017 Q4 7,806,672 $94,381,000 +$94,381,000 $12.09 24